Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Richard H J Begent

Showing results (1-10 of 23) with videos related to

Pageof 3
Sort By:
Expert Opinion on Biological Therapy|October 27, 2004
Antibody-directed enzyme prodrug therapy (ADEPT) for cancerKenneth D Bagshawe, Surinder K Sharma, Richard H J Begent
Current Opinion in Investigational Drugs (London, England : 2000)|July 7, 2005
Advances in antibody-directed enzyme prodrug therapySurinder K Sharma, Kenneth D Bagshawe, Richard H J Begent
Nature Protocols|April 5, 2007
Production of recombinant protein in Pichia pastoris by fermentationBerend Tolner, Lisa Smith, Richard H J Begent, et al.
Nature Protocols|April 5, 2007
Expanded-bed adsorption immobilized-metal affinity chromatographyBerend Tolner, Lisa Smith, Richard H J Begent, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 17, 2007
Combining radioimmunotherapy with antihypoxia therapy 2-deoxy-D-glucose results in reduction of therapeutic efficacyJason L J Dearling, Uzma Qureshi, Richard H J Begent, et al.
Nature Biotechnology|October 8, 2005
NCRI informatics initiativeRichard H J Begent, Peter Kerr, Helen Parkinson, et al.
Bioconjugate Chemistry|January 17, 2002
In vivo tumor delivery of a recombinant single chain Fv::tumor necrosis factor-alpha fusion [correction of factor: a fusion] proteinStephen P Cooke, R Barbara Pedley, R Boden, et al.
Journal of Molecular Biology|June 25, 2002
Reversible dimer formation and stability of the anti-tumour single-chain Fv antibody MFE-23 by neutron scattering, analytical ultracentrifugation, and NMR and FT-IR spectroscopyYie Chia Lee, Mark K Boehm, Kerry A Chester, et al.
Cancer|March 6, 2002
A model-based approach for the optimization of radioimmunotherapy through antibody design and radionuclide selectionAiden A Flynn, Alan J Green, R Barbara Pedley, et al.
European Journal of Cancer (Oxford, England : 1990)|March 15, 2005
Tumour parameters affected by combretastatin A-4 phosphate therapy in a human colorectal xenograft model in nude miceEthaar El-Emir, Geoffrey M Boxer, Ingrid A Petrie, et al.
Pageof 3

Showing results (1-10 of 23) with videos related to

Sort By:
Pageof 3
Expert Opinion on Biological Therapy|October 27, 2004
Antibody-directed enzyme prodrug therapy (ADEPT) for cancerKenneth D Bagshawe, Surinder K Sharma, Richard H J Begent
Current Opinion in Investigational Drugs (London, England : 2000)|July 7, 2005
Advances in antibody-directed enzyme prodrug therapySurinder K Sharma, Kenneth D Bagshawe, Richard H J Begent
Nature Protocols|April 5, 2007
Production of recombinant protein in Pichia pastoris by fermentationBerend Tolner, Lisa Smith, Richard H J Begent, et al.
Nature Protocols|April 5, 2007
Expanded-bed adsorption immobilized-metal affinity chromatographyBerend Tolner, Lisa Smith, Richard H J Begent, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 17, 2007
Combining radioimmunotherapy with antihypoxia therapy 2-deoxy-D-glucose results in reduction of therapeutic efficacyJason L J Dearling, Uzma Qureshi, Richard H J Begent, et al.
Nature Biotechnology|October 8, 2005
NCRI informatics initiativeRichard H J Begent, Peter Kerr, Helen Parkinson, et al.
Bioconjugate Chemistry|January 17, 2002
In vivo tumor delivery of a recombinant single chain Fv::tumor necrosis factor-alpha fusion [correction of factor: a fusion] proteinStephen P Cooke, R Barbara Pedley, R Boden, et al.
Journal of Molecular Biology|June 25, 2002
Reversible dimer formation and stability of the anti-tumour single-chain Fv antibody MFE-23 by neutron scattering, analytical ultracentrifugation, and NMR and FT-IR spectroscopyYie Chia Lee, Mark K Boehm, Kerry A Chester, et al.
Cancer|March 6, 2002
A model-based approach for the optimization of radioimmunotherapy through antibody design and radionuclide selectionAiden A Flynn, Alan J Green, R Barbara Pedley, et al.
European Journal of Cancer (Oxford, England : 1990)|March 15, 2005
Tumour parameters affected by combretastatin A-4 phosphate therapy in a human colorectal xenograft model in nude miceEthaar El-Emir, Geoffrey M Boxer, Ingrid A Petrie, et al.
Pageof 3